Decoglurant
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
5-({7-(Trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}ethynyl)-2-pyridinamine
|
|
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number | 911115-16-7 |
| ATC code | None |
| PubChem | CID 71533696 |
| ChemSpider | 32695160 |
| Chemical data | |
| Formula | C21H11F6N5 |
| Molar mass | 447.336 g/mol |
|
Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.[1][2] Decoglurant progressed as far as phase II clinical trials[1][2] but was ultimately discontinued from further development due to disappointing efficacy results.[3][4]
See also[edit]
References[edit]
- ^ a b "Roche - Pipeline". 2014. Retrieved 2014-08-01.
- ^ a b "Roche Group Development Pipeline" (PDF). 2014. Retrieved 2014-08-01.
- ^ "Roche - Pipeline" (PDF). 2015. Retrieved 2015-05-14.
- ^ Janna Lawrence (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal.
External links[edit]
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
